Incorporating genomics into breast cancer clinical trials and care

Clinical Cancer Research

Volumn 19, Issue 23, 2013, Pages 6371-6379

  Tabchy, Adel ^a   Ma, Cynthia X ^a   Bose, Ron ^a   Ellis, Matthew J ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANASTROZOLE; ANTINEOPLASTIC AGENT; BGJ 398; BUPARLISIB; BYL 719; CYCLIN DEPENDENT KINASE 4 INHIBITOR; CYCLIN DEPENDENT KINASE 6 INHIBITOR; E 3800; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FULVESTRANT; MDM2 INHIBITOR; NERATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PALBOCICLIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PROTEIN INHIBITOR; PROTEIN KINASE B INHIBITOR; RO 5503781; UNCLASSIFIED DRUG; VELIPARIB;

ACCURACY; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER PROGNOSIS; CANCER RESEARCH; CANCER RESISTANCE; CLINICAL TRIAL (TOPIC); DNA SEQUENCE; GENE MUTATION; GENOMICS; HUMAN; MATHEMATICAL MODEL; MOLECULAR EVOLUTION; MUTATIONAL ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; REGISTER; REIMBURSEMENT; SEQUENCE ANALYSIS;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR SEQUENCE ANNOTATION; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 84890293042     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0837     Document Type: Article

References (39)

1. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbBrelated gene ina humanmammarycarcinoma. Science 1985;229:974-6.
2. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-83.
3. Bates SE, Amiri-Kordestani L, Giaccone G. Drug development: portals of discovery. Clin Cancer Res 2012;18:23-32.
4. Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 2013;3:27-34.
5. Garraway L. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol 2013;31:1806-14.
6. Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J Clin Oncol 2013;31:1803-5.
7. Tabchy A, Eltonsy N, Housman DE, Mills GB. Systematic identification of combinatorial drivers and targets in cancer cell lines. PLoS ONE 2013;8:e60339.
8. Meric-Bernstam F, Mills GB. Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol 2012;9:542-8.
9. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009;462:1005-10.
10. Thomas RK, Nickerson E, Simons JF, Janne PA, Tengs T, Yuza Y, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 2006;12:852-5.
11. Perou CM, Sorlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
12. Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 2012;18:4465-72.
13. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
14. Piccart M, Rugo H, Chen D, Campone M, Burris HA III, Taran T, et al. Assessment of genetic alterations in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer from the BOLERO-2 trial by next-generation sequencing IMPAKT conference proceedings. 2013; Abstract 42O-PR.
15. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012;486:395-9.
16. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 2012;486:346-52.
17. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486:400-4.
18. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012;486:405-9.
19. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Wholegenome analysis informs breast cancer response to aromatase inhibition. Nature 2012;486:353-60.
20. Xu S, Li S, Guo Z, Luo J, Ellis MJ, Ma CX. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models. Mol Cancer Ther 2013;12:1665-75.
21. Turner NC, Reis-Filho JS. Tackling the diversity of triple-negative breast cancer. Clin Cancer Res 2013;19:6380-8.
22. Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC. CTG MA.5 randomized trial. Clin Cancer Res 2012;18:2402-12.
23. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013;3:224-37.
24. Ross JS, Wang K, Sheehan CE, Boguniewicz AB, Otto G, Downing SR, et al. Relapsed classic E-Cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res 2013;19:2668-76.
25. Kumar R, Chang L-W, Ellis MJ, Bose R. Prioritizing potentially druggable mutations with dGene: an annotation tool for cancer genome sequencing data. PLoS One 2013;8:e67980.
26. Bardia A, Baselga J. Neoadjuvant therapy as a platform for drug development and approval in breast cancer. Clin Cancer Res 2013;19:6360-70.
27. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 2011;29:2342-9.
28. Schott AF, Hayes DF. Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2012;30:1747-9.
29. Andre F, Bachelot TD, Campone M, Arnedos M, Dieras V, Lacriox-Triki M. Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer patients: a prospective multicentric trial (SAFIR01). J Clin Oncol 2013; suppl: abs 511.
30. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012;338:221.
31. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809-13.
32. Cottu PH, Asselah J, Lae M, Pierga JY, Dieras V, Mignot L, et al. Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol 2008;19:595-7.
33. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-7.
34. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
35. Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012;30:593-9.
36. Beck J, Schutz E, Urnovitz HB, Tabchy A, Mitchell WM, Mills GB. Cell-free DNA copy number variations as a marker for breast cancer in a large study cohort. J Clin Oncol 31, 2013 (suppl; abstr 11013).
37. Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 2012;18:3462-9.
38. Shaw JA, Page K, Blighe K, Hava N, Guttery D, Ward B, et al. Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res 2012;22:220-31.
39. Goldstein TC, Paull EO, Ellis MJ, Stuart JM. Molecular pathways: extracting medical knowledge from high-throughput genomic data. Clin Cancer Res 2013;19:3114-20.